HEALTH

Shoppers Drug Mart, American Scientific Resources partner for private-label VeraTemp

BY Antoinette Alexander

WESTON, Fla. — American Scientific Resources has received a private-label purchase order for a Shoppers Drug Mart VeraTemp noncontact thermometer.

The initial order for 5,000 units will supply VeraTemp to Shoppers Drug Mart’s chain of almost 1,200 Shoppers Drug Mart/Pharmaprix stores across Canada.

The private-label version includes the “Life” Brand logo and packaging insert card to identify the VeraTemp under the Shoppers Drug Mart brand.
With the expansion of the VeraTemp thermometer into the Canadian market via Shoppers Drug Mart, the manufacturer anticipates that the new private label will bolster its distribution into additional retail accounts.

The VeraTemp unit is about the size of a remote control and is powered by two included AAA batteries. To measure a person’s body temperature, aim at the individual’s forehead and press the scan button. The VeraTemp measures the forehead and ambient temperature, completes thousands of calculations with a proprietary algorithm and promises to produce an accurate body temperature reading.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
HEALTH

Op-ed: CHPA, AMA call on Congress to repeal OTC Rx-only FSA provision

BY Michael Johnsen

WASHINGTON — The Consumer Healthcare Products Association last week teamed up with the American Medical Association in a joint op-ed published in Roll Call that called for the repeal of the over-the-counter prescription requirement for flexible spending accounts.

"OTC medications save time and money for the millions of Americans who rely on them to treat many ailments and injuries," wrote CHPA president and CEO Scott Melville and AMA president Peter Carmel. "These medicines play an important role in our nation’s healthcare system, with almost 90% of physicians recommending patients try to address many ailments with self-care interventions, including the use of OTC medication, before seeking professional care."

In the article, Melville and Carmel point to the Restoring Access to Medication Act, which would repeal the prescription requirement, introduced by Sens. Pat Roberts, R-Kan.; and Ben Nelson, D-Neb.; and Reps. Lynn Jenkins, R-Kan., and Shelley Berkley, D-Nev.

According to an associated cost-savings study, $5.2 billion could be saved by consumers and taxpayers annually if only half of the some 10% of unnecessary visits, as reported by doctors, were avoided.

To read the op-ed in its entirety, click here.


Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
HEALTH

P&G and Teva’s joint venture, PGT Healthcare, to form new OTC force

BY Michael Johnsen

CINCINNATI — Procter & Gamble on Thursday announced the creation of a new partnership and joint venture with Teva Pharmaceutical Industries to be named PGT Healthcare.

“This unique and transformational partnership creates one of the broadest and deepest [over-the-counter] product portfolios and geographic footprints in the industry,” Teva president and CEO Shlomo Yanai said. “Each company’s leading brands will experience tremendous growth by combining our strengths. We will be better together.”

The joint venture will be headquartered in Geneva, Switzerland, and will operate in essentially all markets outside of North America. The partnership between P&G and Teva also will develop new brands for the North American market.

PGT Healthcare will focus on best-in-class development and commercialization of branded OTC medicines. The JV will bring together each company’s complementary capabilities and existing over-the-counter medicines. As a result, PGT Healthcare expects to accelerate growth for its parent companies and compete for leadership in the fast-growing, $200 billion consumer healthcare industry. The partnership will start from a solid base of approximately $1.3 billion in annual sales with the potential to grow to $4 billion in annual sales towards the end of the decade.

Under the joint venture, P&G will bring best-in-class consumer understanding, branding, design and in-store merchandising to Teva’s leading brands, such as Ratiopharm — one of Europe’s best-selling generic brands. Teva will bring deeper, broader pharmacy distribution, including its pharmacy sales force and strong pharmacy relationships, broader regulatory capabilities and new technologies to P&G’s leading brands, which include Vicks, Metamucil and Pepto-Bismol.

The joint venture also plans to expand into new OTC categories. Today, P&G has a strong category presence in cough-cold, digestive wellness and women’s diagnostics. Teva’s portfolio includes many technologies and leading brands in other key OTC categories, such as vitamins, minerals and supplements, analgesics, medicated skin, and potential Rx-to-OTC switches.

In connection with the formation of this JV, P&G has sold its OTC plants in Greensboro, N.C. (Vicks production) and Phoenix (Metamucil production) and transferred the employees of both plants to Teva. As part of the partnership, Teva will be the manufacturer and supplier for the PGT Healthcare business and P&G’s North American OTC business.


Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?